2seventy bio-partnered Abecma (idecabtagene vicleucel) is already approved as a fourth-line or later therapy for the blood cancer, and the KarMMa-3 study is designed to support second or third ...

The FDA has not yet assigned a new target action date for the review of the supplemental biologics licence application (sBLA) for Abecma for this patient population of triple-class exposed r/r MM.

Abecma’s review was delayed after the FDA rejected a first filing in May last year, but it’s hoped that the drug could be a significant step forward in the treatment of this incurable condition.

The study is evaluating Abecma (idecabtagene vicleucel; ide-cel) with Revlimid (lenalidomide) maintenance versus lenalidomide ...

Seventy Bio, Inc. ( (TSVT) ) has released its Q3 earnings. Here is a breakdown of the information 2Seventy Bio, Inc. presented to its ...

Abecma US Revenue: $77 million in the third quarter, reflecting a 42% growth over the prior quarter. Projected Abecma US Revenue for 2024: Approximately $240 to $250 million. Collaboration Arrangement ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

CAMBRIDGE, Mass., November 12, 2024--2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent ...

“Abecma continues to show encouraging signs of growth with an expanded label in the third line and a differentiated safety profile. Consistent with our focus on capital allocation and creating ...

These forward-looking statements include statements regarding our strategic plans, timelines and expectations with respect to sales, efficacy and perceived therapeutic benefits of Abecma and ...

2seventy bio, Inc. is a biotechnology company focused on the development and commercialization of CAR T cell therapies, specifically targeting multiple myeloma, with a notable product, Abecma.

The latest announcement is out from 2seventy bio ( (TSVT) ). 2seventy bio reported impressive third-quarter results with a 42% increase in ...